{"_buckets": {"deposit": "746824f8-debd-470c-b2dc-1098c9152edc"}, "_deposit": {"created_by": 17, "id": "2008888", "owner": "17", "owners": [17], "pid": {"revision_id": 0, "type": "depid", "value": "2008888"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:02008888"}, "author_link": [], "item_1615768549627": {"attribute_name": "出版タイプ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_1629683748249": {"attribute_name": "日付", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2024-10-01", "subitem_date_issued_type": "Available"}]}, "item_9_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2023-10", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "4", "bibliographicPageEnd": "471", "bibliographicPageStart": "462", "bibliographicVolumeNumber": "118", "bibliographic_titles": [{"bibliographic_title": "International Journal of Hematology", "bibliographic_titleLang": "en"}]}]}, "item_9_description_4": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "To determine the efficacy of SARS-CoV-2 mRNA vaccination for allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients, we measured antibody titer serially in 92 allo-HSCT patients. Among the evaluable 87 patients, median age at vaccination was 53 years (range, 18–75). The average time between allo-HSCT and vaccination was 3.3 years (range, 0.5–15.7). One month after the second dose, 70 patients (80.5%) had a positive response, whereas 17 patients (19.5%) had a negative response (\u003c 20 U/mL). Only patients older than 44 years had a negative response. Low IgM level was the only significant predictor of vaccine failure in elderly patients. When antibody response before and after the third vaccination was examined in 47 patients, antibodies increased significantly from a median of 18.3 U/mL to 312.6 U/mL (P \u003c 0.01). The median antibody titer after the third vaccination of healthy individuals (n = 203) was 426.4 U/mL, which was comparable to that of patients (P = 0.2). The antibody titer after the third mRNA vaccination increased even in patients whose first two mRNA vaccinations failed. These findings suggest that allo-HSCT recipients should receive the mRNA vaccine regularly.", "subitem_description_language": "en", "subitem_description_type": "Abstract"}]}, "item_9_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Springer", "subitem_publisher_language": "en"}]}, "item_9_relation_43": {"attribute_name": "関連情報", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1007/s12185-023-03648-1", "subitem_relation_type_select": "DOI"}}]}, "item_9_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1007/s12185-023-03648-1", "subitem_rights_language": "en"}]}, "item_9_source_id_7": {"attribute_name": "収録物識別子", "attribute_value_mlt": [{"subitem_source_identifier": "0925-5710", "subitem_source_identifier_type": "PISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "embargoed access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_f1cf"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Takagi, Erina", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Terakura, Seitaro", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Fujigaki, Hidetsugu", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Okamoto, Akinao", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Miyao, Kotaro", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Sawa, Masashi", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Morishita, Takanobu", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Goto, Tatsunori", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Ozawa, Yukiyasu", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Nishida, Tetsuya", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Fukushima, Nobuaki", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Ozeki, Kazutaka", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Hanajiri, Ryo", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Saito, Kuniaki", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Murata, Makoto", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Tomita, Akihiro", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Kiyoi, Hitoshi", "creatorNameLang": "en"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2024-10-01"}], "displaytype": "detail", "download_preview_message": "Download / Preview is available from 2024/9/30.", "file_order": 0, "filename": "RevisedFile_COVID19_ab_draft_20230711.pdf", "filesize": [{"value": "622 KB"}], "format": "application/pdf", "future_date_message": "Download is available from 2024/9/30.", "is_thumbnail": false, "mimetype": "application/pdf", "size": 622000.0, "url": {"objectType": "fulltext", "url": "https://nagoya.repo.nii.ac.jp/record/2008888/files/RevisedFile_COVID19_ab_draft_20230711.pdf"}, "version_id": "694ec337-aaa5-4631-9ee7-b97bff593324"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Antibody response after third dose of COVID-19 mRNA vaccination in allogeneic hematopoietic stem cell transplant recipients is comparable to that in healthy counterparts", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Antibody response after third dose of COVID-19 mRNA vaccination in allogeneic hematopoietic stem cell transplant recipients is comparable to that in healthy counterparts", "subitem_title_language": "en"}]}, "item_type_id": "40001", "owner": "17", "path": ["501"], "permalink_uri": "http://hdl.handle.net/2237/0002008888", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2024-01-19"}, "publish_date": "2024-01-19", "publish_status": "0", "recid": "2008888", "relation": {}, "relation_version_is_last": true, "title": ["Antibody response after third dose of COVID-19 mRNA vaccination in allogeneic hematopoietic stem cell transplant recipients is comparable to that in healthy counterparts"], "weko_shared_id": -1}
Antibody response after third dose of COVID-19 mRNA vaccination in allogeneic hematopoietic stem cell transplant recipients is comparable to that in healthy counterparts
http://hdl.handle.net/2237/0002008888
http://hdl.handle.net/2237/0002008888